Shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) ended Monday session in green amid volatile trading. The shares closed up +0.93 points or 0.93% at $100.77 with 858,118.00 shares getting traded. Post opening the session at $99.36, the shares hit an intraday low of $98.28 and an intraday high of $102.28 and the price vacillated in this range throughout the day. The company has a market cap of $2.40 billion and the numbers of outstanding shares have been calculated to be 263.00 million shares.
GW Pharmaceuticals PLC- ADR (GWPH) announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on Wednesday, 14 September 2016 at 9:55 a.m. EDT.
A live audio webcast of the presentations will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentations.
Shares of Relypsa Inc (NASDAQ:RLYP) ended Monday session at $31.99. The company has a market cap of $1.44 billion and the numbers of outstanding shares have been calculated to be 44.88 million shares.
On Sept. 2, 2016 Galenica Group announced that it has completed its previously announced acquisition of Relypsa, Inc., (RLYP). The combination of Galenica’s Vifor Pharma business unit with Relypsa will create a significant player in cardio-renal care in the US and further strengthen Vifor Pharma’s growing international leadership in cardiology, nephrology and gastroenterology therapies.
Through the acquisition, Vifor Pharma will gain a fully-integrated commercial organisation in the US. With the combination of the commercial assets and best-in-class cardio-renal products of Vifor Pharma, Relypsa and Vifor Fresenius Medical Care Renal Pharma (VFMCRP), Vifor Pharma is positioned to become a major player in the US in its core therapy areas, leveraging its growing specialty portfolio.
“By combining the assets, expertise and commercial strengths of Vifor Pharma and Relypsa, Vifor Pharma is well positioned to become a world-leading specialty pharmaceutical company focused on nephrology, cardiology and gastroenterology medicines,” said Etienne Jornod, Executive Chairman of Galenica and Vifor Pharma. “Vifor Pharma’s portfolio of specialty products will be further enhanced by gaining full global rights to Veltassa(R), an important new treatment for people with hyperkalaemia, and by the ability to increase our visibility with leading nephrologists and cardiologists in the US market. With a first class portfolio of products and rapidly growing global commercial presence, Vifor Pharma is committed to being the partner of choice for patients, clinicians and companies in our core therapy areas.”